Ascendis Pharma A/S (NASDAQ:ASND) Short Interest Up 5.6% in October

Ascendis Pharma A/S (NASDAQ:ASND) was the recipient of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 3,410,000 shares, an increase of 5.6% from the October 15th total of 3,230,000 shares. Based on an average daily trading volume, of 634,100 shares, the days-to-cover ratio is presently 5.4 days.

Ascendis Pharma A/S Trading Down 3.6 %

Shares of ASND stock opened at $122.00 on Tuesday. The stock has a 50-day moving average of $132.40 and a 200-day moving average of $132.47. Ascendis Pharma A/S has a 1-year low of $90.13 and a 1-year high of $161.00. The stock has a market cap of $7.40 billion, a price-to-earnings ratio of -15.10 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. Sell-side analysts forecast that Ascendis Pharma A/S will post -7.3 earnings per share for the current year.

Analysts Set New Price Targets

ASND has been the topic of several analyst reports. Evercore ISI increased their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 17th. Wedbush reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a report on Friday. JPMorgan Chase & Co. dropped their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research report on Wednesday, October 23rd. Jefferies Financial Group lifted their target price on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research report on Tuesday, August 13th. Finally, Wells Fargo & Company boosted their target price on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $191.77.

Hedge Funds Weigh In On Ascendis Pharma A/S

Hedge funds and other institutional investors have recently bought and sold shares of the company. Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S during the 3rd quarter worth about $60,000. Price T Rowe Associates Inc. MD lifted its stake in Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after buying an additional 336,976 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock worth $625,075,000 after buying an additional 267,881 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Ascendis Pharma A/S by 1,461.1% during the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after buying an additional 234,446 shares in the last quarter. Finally, Avoro Capital Advisors LLC increased its stake in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after acquiring an additional 229,995 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.